1. Home
  2. SCLXW vs MEVO Comparison

SCLXW vs MEVO Comparison

Compare SCLXW & MEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.20

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

MEVO

M Evo Global Acquisition Corp II Class A Ordinary Shares

N/A

Current Price

$9.89

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLXW
MEVO
Founded
N/A
2025
Country
United States
United States
Employees
30
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
SCLXW
MEVO
Price
$0.20
$9.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.2K
45.4K
Earning Date
03-07-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,152,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.02
N/A
52 Week Low
$0.04
$9.83
52 Week High
$0.64
$9.94

Technical Indicators

Market Signals
Indicator
SCLXW
MEVO
Relative Strength Index (RSI) 60.28 59.50
Support Level $0.09 $9.83
Resistance Level $0.30 $9.90
Average True Range (ATR) 0.02 0.00
MACD 0.01 0.00
Stochastic Oscillator 84.39 80.00

Price Performance

Historical Comparison
SCLXW
MEVO

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: